Stockreport

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Vir...

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
PDF CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineerin [Read more]